Table 1.
Immune checkpoint inhibitors in HCC [32]
| Targetcell | Molecule | Develop. code | Drug name | TM name | Antibody class | Company |
|---|---|---|---|---|---|---|
| Tcell | PD-1 | BMS-36558 ONO-4538 |
Nivolumab | Opdivo | Fully human IgG4 antibody | ONO/BMS |
| PD-1 | MK-4375 | Pembrolizumab | Keytruda | Humanized IgG4 antibody | Merck | |
| PD-1 | BGB-A317 | Tislelizumab | Not approved | Humanized IgG4 antibody | BeiGene | |
| PD-1 | SHR-1210 | Camrelizumab | Not approved | Humanized IgG4 antibody | Jiangsu HengRui Medicine | |
| Tumor cell | PD-L1 | MPDL3280A | Atezolizumab | Tecentriq | Fully human IgG1 antibody | Roche |
| PD-L1 | MEDI4736 | Durvalumab | Imfinzi | humanized IgG1 antibody | AstraZeneca | |
| PD-L1 | MSB-0010718C | Avelumab | Barencio | Humanized IgG1 antibody | Merck-Serono | |
| Tcell | CTLA-4 | BMS-734016 | Ipilimumab | Yervoy | Fully humanized IgG1 antibody | BMS Medarex |
| CTLA-4 | MEDI1123 | Tremelimumab | Not approved | fully humanized IgG2 antibody | Astrazeneca MedImmune | |